X
Record #19348

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Original paper date
Jun 5, 2017
Institution
German Breast Group, Neu-Isenburg, Germany · Frontier Science (Scotland), Kincraig, United Kingdom · Breast European Adjuvant Study Team (BrEAST) Data Center, Brussels, Belgium · Breast International Group, Brussels, Belgium · Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium · Roche Pharma, Bern, Switzerland · Department of Cardiology, Cardio-Oncology, Bern University Hospital, Bern, Switzerland · Department of Pathology, European Institute of Oncology, University of Milan, Milan, Italy · National Institute of Oncology, Budapest, Hungary · Centre François Baclesse, Caen, France · the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, USA · Instituto Nacional de Câncer, Rio de Janeiro, Brazil · Dana–Farber Cancer Institute, Harvard Medical School, Harvard T. H. Chan School of Public Health, Boston, USA · Frontier Science and Technology Research Foundation, Boston, USA · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
Open access
No
Article type
Clinical Study
Broad categories
(BLS) Genetics(HSC) Medicine - Obstetrics/Gynecology(HSC) Medicine - Oncology(HSC) Medicine - Pharmacology(HSC) Medicine - Rehabilitation/Therapy
Citation lifecycle

How this paper is being cited

Pre-retraction
24
Same day
0
Post-retraction
1,294
% post-retraction
650.3%
~120.1 citations/yr before retraction · ~142.5 citations/yr after
— citing papers

Who is still citing this work

Loading…
Back to browse